甲基1-甲基-1H-苯并咪唑-6-羧酸酯 | 131020-50-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 甲基1-甲基-1H-苯并咪唑-6-羧酸酯
• 中文别名: 1-甲基-1H-苯并咪唑-6-羧酸甲酯
• 英文名称: methyl 1-methyl-1H-benzo[d]imidazole-6-carboxylate
• 英文别名: methyl 3-methylbenzimidazole-5-carboxylate
• CAS: 131020-50-3
• 化学式: C₁₀H₁₀N₂O₂
• mdl: MFCD11973677
• 分子量: 190.202
• InChiKey: SQVPAFJTHBHULZ-UHFFFAOYSA-N

物化性质

• 沸点：
  334.1±34.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  甲基1-甲基-1H-苯并咪唑-6-羧酸酯 在 一水合肼 作用下， 以65%的产率得到1-methyl-1H-benzimidazole-6-carbohydrazide
  参考文献：
  名称：

  Design, synthesis and structure–activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β

  摘要：

  Glycogen synthase kinase-3beta (GSK-3beta) is implicated in abnormal hyperphosphorylation of tau protein and its inhibitors are expected to be a promising therapeutic agents for the treatment of Alzheimer's disease. Here we report design, synthesis and structure-activity relationships of a novel series of oxadiazole derivatives as GSK-3beta inhibitors. Among these inhibitors, compound 20x showed highly selective and potent GSK-3beta inhibitory activity in vitro and its binding mode was determined by obtaining the X-ray co-crystal structure of 20x and GSK-3beta.

  DOI：

  10.1016/j.bmc.2009.01.019
• 作为产物：
  描述：

  3-(甲基氨基)-4-硝基苯羧酸甲酯 在 溶剂黄146 、 锌 作用下， 以 甲醇 为溶剂， 反应 14.0h， 生成 甲基1-甲基-1H-苯并咪唑-6-羧酸酯
  参考文献：
  名称：

  Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

  摘要：

  DOI：

  10.1021/acs.jmedchem.1c01196

文献信息

• [EN] PRMT5 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PRMT5 ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100695A1

  公开（公告）日：2014-06-26

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• GSK-3BETAINHIBITOR
  申请人：Itoh Fumio

  公开号：US20100069381A1

  公开（公告）日：2010-03-18

  For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

  为了提供一种含有噁二唑化合物或其盐或其前药的GSK-3β抑制剂，用作GSK-3β相关病理或疾病的预防或治疗剂，本发明提供了一种含有由以下式（I）表示的化合物的GSK-3β抑制剂： 其中每个符号如规范中定义，或其盐或其前药。
• Neutrophil inhibitors to reduce inflammatory response
  申请人：The Procter & Gamble Company

  公开号：US20040006104A1

  公开（公告）日：2004-01-08

  The invention provides novel compounds selected from the group consisting of: 1 The compounds of the present invention are useful for the treatment and prevention of a variety of diseases and conditions associated with undesirable or abnormal inflammatory responses, such as ischemia-reperfusion injury. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment or prevention for the above disorders using theses compounds or the compositions containing them.

  该发明提供了从以下组合中选择的新化合物：1本发明的化合物对治疗和预防与不良或异常炎症反应相关的各种疾病和病况，如缺血再灌注损伤，具有益处。因此，该发明还提供了包括这些化合物的药物组合物。该发明还提供了使用这些化合物或含有它们的组合物进行上述疾病的治疗或预防的方法。
• Iron-catalyzed [3 + 2]-cycloaddition of <i>in situ</i> generated <i>N</i>-ylides with alkynes or olefins: access to multi-substituted/polycyclic pyrrole derivatives
  作者：Kai Zhou、Ming Bao、Jingjing Huang、Zhenghui Kang、Xinfang Xu、Wenhao Hu、Yu Qian

  DOI：10.1039/c9ob02571e

  日期：——

  An iron-catalyzed one-pot three-component reaction of 1-substituted benzimidazoles with diazoacetates and electron-deficient alkynes or alkenes has been reported. Mechanistically, the reaction goes through a 1,3-dipolar cycloaddition of catalytically generated benzimidazolium N-ylides with various activated alkynes or alkenes, leading to multi-substituted and polycyclic fused pyrrole derivatives, respectively

  已经报道了铁取代的1-取代的苯并咪唑与重氮乙酸酯和缺电子的炔烃或烯烃的一锅三组分反应。从机理上讲，该反应是通过催化生成的苯并咪唑N-基化物与各种活化的炔烃或烯烃进行1，3-偶极环加成，分别得到多取代的和多环稠合的吡咯衍生物。
• PRMT5 INHIBITORS AND USES THEREOF
  申请人：Epizyme, Inc.

  公开号：US20150133427A1

  公开（公告）日：2015-05-14

  Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了公式(I)的化合物及其药学上可接受的盐和药物组合物。本发明的化合物对于抑制PRMT5活性是有用的。还描述了使用这些化合物治疗PRMT5介导的疾病的方法。